NO326600B1 - S-metylisotiouroniumdimetylfosfat, farmasoytisk sammensetning samt anvendelse av S-alkylisotiouronium derivater for fremstilling av et medikament for okning av arterielt blodtrykk - Google Patents
S-metylisotiouroniumdimetylfosfat, farmasoytisk sammensetning samt anvendelse av S-alkylisotiouronium derivater for fremstilling av et medikament for okning av arterielt blodtrykk Download PDFInfo
- Publication number
- NO326600B1 NO326600B1 NO19991419A NO991419A NO326600B1 NO 326600 B1 NO326600 B1 NO 326600B1 NO 19991419 A NO19991419 A NO 19991419A NO 991419 A NO991419 A NO 991419A NO 326600 B1 NO326600 B1 NO 326600B1
- Authority
- NO
- Norway
- Prior art keywords
- ethylisothiouronium
- drug
- use according
- compound
- formula
- Prior art date
Links
- 230000004872 arterial blood pressure Effects 0.000 title claims description 60
- 239000003814 drug Substances 0.000 title claims description 32
- 229940079593 drug Drugs 0.000 title claims description 28
- YFEHFLUEQSONBX-UHFFFAOYSA-N [amino(methylsulfanyl)methylidene]azanium;dimethyl phosphate Chemical compound CSC(N)=N.COP(O)(=O)OC YFEHFLUEQSONBX-UHFFFAOYSA-N 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 208000001953 Hypotension Diseases 0.000 claims abstract description 11
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 claims description 71
- 238000002360 preparation method Methods 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- UJRHNBBBWMFTKQ-UHFFFAOYSA-N CC(C)OP(O)O.CC(C)SC(N)=N.CC(C)SC(N)=N Chemical compound CC(C)OP(O)O.CC(C)SC(N)=N.CC(C)SC(N)=N UJRHNBBBWMFTKQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 6
- CYYJBBMXGOJTIQ-UHFFFAOYSA-N CCCOP(O)O.CCCSC(N)=N.CCCSC(N)=N Chemical compound CCCOP(O)O.CCCSC(N)=N.CCCSC(N)=N CYYJBBMXGOJTIQ-UHFFFAOYSA-N 0.000 claims description 4
- SUDLUXBNOZCRIJ-UHFFFAOYSA-N [amino(butylsulfanyl)methylidene]azanium;dibutyl phosphate Chemical compound CCCCSC(N)=N.CCCCOP(O)(=O)OCCCC SUDLUXBNOZCRIJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- XSXAFBUBMLOYIX-UHFFFAOYSA-N ethyl carbamimidothioate ethyl dihydrogen phosphite Chemical compound CCOP(O)O.CCSC(N)=N.CCSC(N)=N XSXAFBUBMLOYIX-UHFFFAOYSA-N 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- NXHQGHMUIRHPLZ-UHFFFAOYSA-N CC(C)COP(O)O.CC(C)CSC(N)=N.CC(C)CSC(N)=N Chemical compound CC(C)COP(O)O.CC(C)CSC(N)=N.CC(C)CSC(N)=N NXHQGHMUIRHPLZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000001450 anions Chemical group 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 208000012866 low blood pressure Diseases 0.000 claims 1
- VFIZBHJTOHUOEK-UHFFFAOYSA-N s-ethylisothiourea Chemical compound CCSC(N)=N VFIZBHJTOHUOEK-UHFFFAOYSA-N 0.000 claims 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims 1
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 18
- 229910052760 oxygen Inorganic materials 0.000 abstract description 18
- 239000001301 oxygen Substances 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 13
- 208000032843 Hemorrhage Diseases 0.000 abstract description 6
- 231100000572 poisoning Toxicity 0.000 abstract description 6
- 230000000607 poisoning effect Effects 0.000 abstract description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 5
- 239000011574 phosphorus Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- 230000000222 hyperoxic effect Effects 0.000 abstract description 4
- 230000035939 shock Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract description 2
- 208000011861 acute hypotension Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 57
- 239000008280 blood Substances 0.000 description 57
- 238000002347 injection Methods 0.000 description 33
- 239000007924 injection Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 24
- 230000036387 respiratory rate Effects 0.000 description 21
- 210000002216 heart Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 230000001154 acute effect Effects 0.000 description 17
- 238000010253 intravenous injection Methods 0.000 description 16
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000001631 hypertensive effect Effects 0.000 description 14
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 14
- 241000282326 Felis catus Species 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000036581 peripheral resistance Effects 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 208000010444 Acidosis Diseases 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010027417 Metabolic acidosis Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 208000006218 bradycardia Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000000004 hemodynamic effect Effects 0.000 description 8
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000036471 bradycardia Effects 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 229960001802 phenylephrine Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010049771 Shock haemorrhagic Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000004873 systolic arterial blood pressure Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000002692 epidural anesthesia Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 4
- 229960001289 prazosin Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 3
- 206010058490 Hyperoxia Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229950002932 hexamethonium Drugs 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- OSBXGLCAOCDMAR-UHFFFAOYSA-N COP(O)O.CSC(N)=N.CSC(N)=N Chemical compound COP(O)O.CSC(N)=N.CSC(N)=N OSBXGLCAOCDMAR-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000003826 Respiratory Acidosis Diseases 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003457 ganglion blocking agent Substances 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004223 radioprotective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- SWXXKWPYNMZFTE-UHFFFAOYSA-N (c-ethylsulfanylcarbonimidoyl)azanium;bromide Chemical compound Br.CCSC(N)=N SWXXKWPYNMZFTE-UHFFFAOYSA-N 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- AOCFNTFUZJXAHA-UHFFFAOYSA-N CC[S+]=C(N)N Chemical compound CC[S+]=C(N)N AOCFNTFUZJXAHA-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010045937 Felypressin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000055026 Protein O-Methyltransferase Human genes 0.000 description 1
- 108700040119 Protein O-Methyltransferase Proteins 0.000 description 1
- 206010038664 Respiratory alkalosis Diseases 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000001325 cardiostimulating effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 108010071981 cyanhemoglobin Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- NFORZJQPTUSMRL-UHFFFAOYSA-N dipropan-2-yl hydrogen phosphite Chemical compound CC(C)OP(O)OC(C)C NFORZJQPTUSMRL-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- SFKQVVDKFKYTNA-DZCXQCEKSA-N felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 description 1
- 229960001527 felypressin Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- -1 glycogon Proteins 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940102212 intraperitoneal solution Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU96119163A RU2142796C1 (ru) | 1996-09-26 | 1996-09-26 | Лекарственное противошоковое средство |
| RU97115433/14A RU2187309C2 (ru) | 1997-09-19 | 1997-09-19 | Средство, влияющее на артериальное давление |
| PCT/IL1997/000314 WO1998013036A1 (en) | 1996-09-26 | 1997-09-25 | Pharmaceutical compositions comprising s-alkylisothiouronium derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991419D0 NO991419D0 (no) | 1999-03-24 |
| NO991419L NO991419L (no) | 1999-05-21 |
| NO326600B1 true NO326600B1 (no) | 2009-01-19 |
Family
ID=26653892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991419A NO326600B1 (no) | 1996-09-26 | 1999-03-24 | S-metylisotiouroniumdimetylfosfat, farmasoytisk sammensetning samt anvendelse av S-alkylisotiouronium derivater for fremstilling av et medikament for okning av arterielt blodtrykk |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6160008A (ko) |
| EP (1) | EP0928191B1 (ko) |
| JP (1) | JP4260888B2 (ko) |
| KR (1) | KR100575507B1 (ko) |
| CN (1) | CN1116871C (ko) |
| AT (1) | ATE222758T1 (ko) |
| AU (1) | AU717712B2 (ko) |
| BR (1) | BR9712851A (ko) |
| CA (1) | CA2266533C (ko) |
| DE (1) | DE69715013T2 (ko) |
| DK (1) | DK0928191T3 (ko) |
| ES (1) | ES2182116T3 (ko) |
| HK (1) | HK1022833A1 (ko) |
| IL (1) | IL129020A (ko) |
| NO (1) | NO326600B1 (ko) |
| PT (1) | PT928191E (ko) |
| TR (1) | TR199900783T2 (ko) |
| WO (1) | WO1998013036A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2296792T3 (es) * | 2000-09-05 | 2008-05-01 | Meditor Pharmaceuticals Ltd. | Composiciones farmaceuticas para cefalea, ,migraña, nauseas y emesis. |
| JP2009507068A (ja) * | 2005-09-06 | 2009-02-19 | メディター ファーマスーティカルズ リミテッド | 血液透析患者における低血圧予防及び血圧安定化 |
| US20090186854A1 (en) * | 2006-03-23 | 2009-07-23 | Meditor Pharmaceuticals Ltd. | S-alkylisothiouronium derivatives for the treatment of inflammatory diseases |
| US20100285127A1 (en) * | 2007-06-13 | 2010-11-11 | Refael Barkan | Taste masked pharmaceutical compositions of s-alkylisothiouronium derivatives |
| US12011423B2 (en) | 2007-11-06 | 2024-06-18 | Foraviset Ltd. | S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders |
| EP2219447B1 (en) * | 2007-11-06 | 2013-07-03 | Barkan-Farma S.r.l. | S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders |
| MD3619G2 (ro) * | 2007-11-06 | 2009-01-31 | Рафаэль Баркан | Remediu medicamentos nazal cu acţiune anticongestivă |
| CN104140386A (zh) * | 2014-02-12 | 2014-11-12 | 上海应用技术学院 | 一种2-苄基-异硫脲三氟乙酸盐的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3123636A (en) * | 1964-03-03 | Thiuronium h alii | ||
| US3116327A (en) * | 1960-07-22 | 1963-12-31 | Baxter Laboratories Inc | Upsilon-dimethylaminopropyl isothiourea and acid addition salts thereof |
| US3657337A (en) * | 1967-12-04 | 1972-04-18 | Sandoz Ag | Benzylideneamino guanidines |
| FR2419675A1 (fr) * | 1978-03-16 | 1979-10-12 | Philagro Sa | Compositions fongicides a base de phosphites d'isothiouronium |
| AT395012B (de) * | 1986-06-27 | 1992-08-25 | Richter Gedeon Vegyeszet | Verfahren zur herstellung von n-(1(s)|thoxycarbonyl-3-phenyl-propyl)-(s)-alanyl-(s)prolin und von dessen saeureadditionssalzen |
-
1997
- 1997-09-25 ES ES97941178T patent/ES2182116T3/es not_active Expired - Lifetime
- 1997-09-25 AT AT97941178T patent/ATE222758T1/de active
- 1997-09-25 AU AU43178/97A patent/AU717712B2/en not_active Ceased
- 1997-09-25 BR BR9712851-1A patent/BR9712851A/pt not_active IP Right Cessation
- 1997-09-25 JP JP51546498A patent/JP4260888B2/ja not_active Expired - Fee Related
- 1997-09-25 KR KR1019997002578A patent/KR100575507B1/ko not_active IP Right Cessation
- 1997-09-25 US US09/269,405 patent/US6160008A/en not_active Expired - Fee Related
- 1997-09-25 DK DK97941178T patent/DK0928191T3/da active
- 1997-09-25 EP EP97941178A patent/EP0928191B1/en not_active Expired - Lifetime
- 1997-09-25 PT PT97941178T patent/PT928191E/pt unknown
- 1997-09-25 CN CN97199137A patent/CN1116871C/zh not_active Expired - Fee Related
- 1997-09-25 WO PCT/IL1997/000314 patent/WO1998013036A1/en active IP Right Grant
- 1997-09-25 TR TR1999/00783T patent/TR199900783T2/xx unknown
- 1997-09-25 IL IL12902097A patent/IL129020A/en not_active IP Right Cessation
- 1997-09-25 DE DE69715013T patent/DE69715013T2/de not_active Expired - Lifetime
- 1997-09-25 CA CA002266533A patent/CA2266533C/en not_active Expired - Fee Related
-
1999
- 1999-03-24 NO NO19991419A patent/NO326600B1/no not_active IP Right Cessation
-
2000
- 2000-03-23 HK HK00101803A patent/HK1022833A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2266533A1 (en) | 1998-04-02 |
| JP4260888B2 (ja) | 2009-04-30 |
| AU4317897A (en) | 1998-04-17 |
| DE69715013D1 (de) | 2002-10-02 |
| AU717712B2 (en) | 2000-03-30 |
| EP0928191B1 (en) | 2002-08-28 |
| ATE222758T1 (de) | 2002-09-15 |
| ES2182116T3 (es) | 2003-03-01 |
| KR20000048636A (ko) | 2000-07-25 |
| TR199900783T2 (xx) | 1999-07-21 |
| NO991419L (no) | 1999-05-21 |
| EP0928191A1 (en) | 1999-07-14 |
| CN1234737A (zh) | 1999-11-10 |
| US6160008A (en) | 2000-12-12 |
| DE69715013T2 (de) | 2003-05-22 |
| JP2001501928A (ja) | 2001-02-13 |
| IL129020A0 (en) | 2000-02-17 |
| PT928191E (pt) | 2003-01-31 |
| NO991419D0 (no) | 1999-03-24 |
| CN1116871C (zh) | 2003-08-06 |
| BR9712851A (pt) | 2000-01-18 |
| DK0928191T3 (da) | 2002-12-30 |
| KR100575507B1 (ko) | 2006-05-03 |
| WO1998013036A1 (en) | 1998-04-02 |
| CA2266533C (en) | 2007-08-07 |
| IL129020A (en) | 2004-06-20 |
| HK1022833A1 (en) | 2000-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2152487C (en) | Method for treating a medical patient for cardiac trauma | |
| JPH0639383B2 (ja) | 医薬組成物 | |
| BROOKS et al. | Role of brain prostaglandins in the control of vasopressin secretion in the conscious rat | |
| Downing et al. | Myocardial hibernation in the ischemic neonatal heart. | |
| NO326600B1 (no) | S-metylisotiouroniumdimetylfosfat, farmasoytisk sammensetning samt anvendelse av S-alkylisotiouronium derivater for fremstilling av et medikament for okning av arterielt blodtrykk | |
| US5541225A (en) | α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia | |
| RU2327228C1 (ru) | Способ моделирования кардиовазоренальной артериальной гипертензии у крыс | |
| DE69629282T2 (de) | Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern | |
| RU2283114C1 (ru) | Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы | |
| JPS63501497A (ja) | 選択的冠血管拡張剤 | |
| JPS6258336B2 (ko) | ||
| RU2187309C2 (ru) | Средство, влияющее на артериальное давление | |
| DE2743704C2 (de) | L- oder DL-Phenylglycine enthaltende Arzneimittel | |
| US20040072801A1 (en) | Sterols bearing pendant allosteric effectors of hemoglobin, and uses thereof | |
| RU2552529C1 (ru) | Вазопрессорное средство | |
| CN117257803B (zh) | 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用 | |
| Dabrowski et al. | The efficiency of magnesium supplementation in patients undergoing cardiopulmonary bypass: changes in serum magnesium concentrations and atrial fibrillation episodes | |
| RU2338538C1 (ru) | Антигипотензивное средство | |
| CN115916201B (zh) | 药剂诱发性心动过缓及心动过缓性心律失常治疗药 | |
| WO2021054473A1 (ja) | 鎌状赤血球症の改善及び／又は予防剤 | |
| Heikkinen et al. | Apotransferrin, C1‐esterase inhibitor, and alpha 1‐acid glycoprotein for cerebral protection during experimental hypothermic circulatory arrest | |
| WO1999004783A1 (en) | Composition for protection from damage by ischemia | |
| RU2122415C1 (ru) | Способ интенсивной терапии у больных с травматическим шоком | |
| Heard et al. | A CLINICAL AND EXPERIMENTAL INVESTIGATION OF THE THERAPEUTIC VALUE OF CAMPHOR. | |
| WO2001015705A1 (en) | Use of fructose-1,6-diphosphate as an inotrope drug for cardiopulmonary bypass surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |